{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:20:10Z","timestamp":1790889610295,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T00:00:00Z","timestamp":1712275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T00:00:00Z","timestamp":1712275200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s10147-024-02502-6","type":"journal-article","created":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T07:02:06Z","timestamp":1712300526000},"page":"689-699","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effectiveness of G-CSF in chemotherapy for digestive system tumors: a systematic review of the Clinical Practice Guidelines for the Use of G-CSF 2022 delineated by the Japan Society of Clinical Oncology"],"prefix":"10.1007","volume":"29","author":[{"given":"Mamoru","family":"Ito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Okumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Nio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eishi","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukinori","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiki","family":"Ichihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuhiro","family":"Yoshinami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Susumu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munetaka","family":"Takekuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Motohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Ochi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Uchino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaro","family":"Kamiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinobu","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitomi","family":"Nishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhisa","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimi","family":"Takano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9014-6382","authenticated-orcid":false,"given":"Kenji","family":"Tsuchihashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,5]]},"reference":[{"key":"2502_CR1","unstructured":"Cancer Information Service, National Cancer Center, Japan. https:\/\/ganjoho.jp\/reg_stat\/statistics\/stat\/summary.html. Accessed 29 Jan 2024"},{"key":"2502_CR2","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1016\/S0140-6736(14)62048-1","volume":"385","author":"L Del Mastro","year":"2015","unstructured":"Del Mastro L, De Placido S, Bruzzi P et al (2015) Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 \u00d7 2 factorial, randomised phase 3 trial. Lancet 385:1863\u20131872. https:\/\/doi.org\/10.1016\/S0140-6736(14)62048-1","journal-title":"Lancet"},{"key":"2502_CR3","unstructured":"The Japan Society of Clinical Oncology (2022) Clinical Practice Guidelines for the Use of G-CSF. KANEHARA & CO., LTD."},{"key":"2502_CR4","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","volume":"33","author":"TJ Smith","year":"2015","unstructured":"Smith TJ, Bohlke K, Lyman GH et al (2015) Recommendations for the use of WBC growth factors: American society of clinical oncology clinical practice guideline update. J Clin Oncol 33:3199\u20133212. https:\/\/doi.org\/10.1200\/JCO.2015.62.3488","journal-title":"J Clin Oncol"},{"key":"2502_CR5","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","volume":"47","author":"MS Aapro","year":"2011","unstructured":"Aapro MS, Bohlius J, Cameron DA et al (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47:8\u201332. https:\/\/doi.org\/10.1016\/j.ejca.2010.10.013","journal-title":"Eur J Cancer"},{"key":"2502_CR6","unstructured":"NCCN Clinical Practice Guideline: hematopoietic growth factors. Version 2, 2024. Accessed 30 Dec 30 2023"},{"key":"2502_CR7","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jclinepi.2012.03.013","volume":"66","author":"J Andrews","year":"2013","unstructured":"Andrews J, Guyatt G, Oxman AD et al (2013) GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol 66:719\u2013725. https:\/\/doi.org\/10.1016\/j.jclinepi.2012.03.013","journal-title":"J Clin Epidemiol"},{"key":"2502_CR8","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.jclinepi.2013.02.003","volume":"66","author":"JC Andrews","year":"2013","unstructured":"Andrews JC, Sch\u00fcnemann HJ, Oxman AD et al (2013) GRADE guidelines: 15. Going from evidence to recommendation\u2014determinants of a recommendation\u2019s direction and strength. J Clin Epidemiol 66:726\u2013735. https:\/\/doi.org\/10.1016\/j.jclinepi.2013.02.003","journal-title":"J Clin Epidemiol"},{"key":"2502_CR9","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1200\/JCO.2017.75.5587","volume":"36","author":"YL Wu","year":"2018","unstructured":"Wu YL, Yang JCH, Kim DW et al (2018) Phase II study of crizotinib in east asian patients with ROS1-positive advanced non\u2013small-cell lung cancer. J Clin Oncol 36:1405\u20131411. https:\/\/doi.org\/10.1200\/JCO.2017.75.5587","journal-title":"J Clin Oncol"},{"key":"2502_CR10","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1691\/ph.2018.8576","volume":"73","author":"Y Yoshida","year":"2018","unstructured":"Yoshida Y, Komori K, Aoki M et al (2018) Efficacy of pegfilgrastim administration in patients with esophageal cancer treated with docetaxel, cisplatin, and 5-fluorouracil. Pharmazie 73:613\u2013616. https:\/\/doi.org\/10.1691\/ph.2018.8576","journal-title":"Pharmazie"},{"key":"2502_CR11","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s10147-018-1306-3","volume":"23","author":"M Kawahira","year":"2018","unstructured":"Kawahira M, Yokota T, Hamauchi S et al (2018) Primary prophylactic granulocyte colony-stimulating factor according to ASCO guidelines has no preventive effect on febrile neutropenia in patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy. Int J Clin Oncol 23:1189\u20131195. https:\/\/doi.org\/10.1007\/s10147-018-1306-3","journal-title":"Int J Clin Oncol"},{"key":"2502_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12957-019-1665-x","volume":"17","author":"Y Ohkura","year":"2019","unstructured":"Ohkura Y, Ueno M, Udagawa H (2019) Risk factors for febrile neutropenia and effectiveness of primary prophylaxis with pegfilgrastim in patients with esophageal cancer treated with docetaxel, cisplatin, and 5-fluorouracil. World J Surg Oncol 17:1\u20136. https:\/\/doi.org\/10.1186\/s12957-019-1665-x","journal-title":"World J Surg Oncol"},{"key":"2502_CR13","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","volume":"23","author":"YK Kang","year":"2022","unstructured":"Kang YK, Chen LT, Ryu MH et al (2022) Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-contr. Lancet Oncol 23:234\u2013247. https:\/\/doi.org\/10.1016\/S1470-2045(21)00692-6","journal-title":"Lancet Oncol"},{"key":"2502_CR14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M et al (2021) First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398:27\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(21)00797-2","journal-title":"Lancet"},{"key":"2502_CR15","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/nejmoa2004413","volume":"382","author":"K Shitara","year":"2020","unstructured":"Shitara K, Bang Y-J, Iwasa S et al (2020) Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med 382:2419\u20132430. https:\/\/doi.org\/10.1056\/nejmoa2004413","journal-title":"N Engl J Med"},{"key":"2502_CR16","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.clcc.2014.09.005","volume":"13","author":"SY Moorcraft","year":"2014","unstructured":"Moorcraft SY, Khan K, Peckitt C et al (2014) FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience. Clin Colorectal Cancer 13:232\u2013238. https:\/\/doi.org\/10.1016\/j.clcc.2014.09.005","journal-title":"Clin Colorectal Cancer"},{"key":"2502_CR17","first-page":"1678","volume":"43","author":"R Ninomiya","year":"2016","unstructured":"Ninomiya R, Nakazawa A, Miyata Y et al (2016) Primary prophylactic administration of pegfilgrastim in FOLFIRINOX therapy for locally advanced pancreatic carcinoma. Gan To Kagaku Ryoho 43:1678\u20131680","journal-title":"Gan To Kagaku Ryoho"},{"key":"2502_CR18","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ejca.2017.02.010","volume":"76","author":"J Lee","year":"2017","unstructured":"Lee J, Kim JW, Ahn S et al (2017) Optimal dose reduction of FOLFIRINOX for preserving tumour response in advanced pancreatic cancer: using cumulative relative dose intensity. Eur J Cancer 76:125\u2013133. https:\/\/doi.org\/10.1016\/j.ejca.2017.02.010","journal-title":"Eur J Cancer"},{"key":"2502_CR19","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.clcc.2016.08.008","volume":"16","author":"T Pinter","year":"2017","unstructured":"Pinter T, Klippel Z, Cesas A et al (2017) A phase III, randomized, double-blind, placebo-controlled trial of pegfilgrastim in patients receiving first-line FOLFOX\/bevacizumab or FOLFIRI\/bevacizumab for locally advanced or metastatic colorectal cancer: final results of the pegfilgrastim and anti-V. Clin Colorectal Cancer 16:103-114.e3. https:\/\/doi.org\/10.1016\/j.clcc.2016.08.008","journal-title":"Clin Colorectal Cancer"},{"key":"2502_CR20","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3816\/CCC.2010.n.013","volume":"9","author":"JR Hecht","year":"2010","unstructured":"Hecht JR, Pillai M, Gollard R et al (2010) A randomized, placebo-controlled phase II study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy. Clin Colorectal Cancer 9:95\u2013101. https:\/\/doi.org\/10.3816\/CCC.2010.n.013","journal-title":"Clin Colorectal Cancer"},{"key":"2502_CR21","doi-asserted-by":"publisher","first-page":"3754","DOI":"10.1111\/cas.14218","volume":"110","author":"T Ishikawa","year":"2019","unstructured":"Ishikawa T, Yasuda T, Okayama T et al (2019) Early administration of pegfilgrastim for esophageal cancer treated with docetaxel, cisplatin, and fluorouracil: a phase II study. Cancer Sci 110:3754\u20133760. https:\/\/doi.org\/10.1111\/cas.14218","journal-title":"Cancer Sci"},{"key":"2502_CR22","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/s0140-6736(21)01234-4","volume":"398","author":"J-M Sun","year":"2021","unstructured":"Sun J-M, Shen L, Shah MA et al (2021) Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet 398:759\u2013771. https:\/\/doi.org\/10.1016\/s0140-6736(21)01234-4","journal-title":"Lancet"},{"key":"2502_CR23","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1200\/JCO.2022.40.4_suppl.238","volume":"40","author":"K Kato","year":"2022","unstructured":"Kato K, Ito Y, Daiko H et al (2022) A randomized controlled phase III trial comparing two chemotherapy regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced esophageal cancer, JCOG1109 NExT study. J Clin Oncol 40:238. https:\/\/doi.org\/10.1200\/JCO.2022.40.4_suppl.238","journal-title":"J Clin Oncol"},{"key":"2502_CR24","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.annonc.2022.05.522","volume":"33","author":"E Pleasance","year":"2022","unstructured":"Pleasance E, Bohm A, Williamson LM et al (2022) Whole-genome and transcriptome analysis enhances precision cancer treatment options. Ann Oncol 33:939\u2013949. https:\/\/doi.org\/10.1016\/j.annonc.2022.05.522","journal-title":"Ann Oncol"},{"key":"2502_CR25","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817\u20131825. https:\/\/doi.org\/10.1056\/NEJMoa1011923","journal-title":"N Engl J Med"},{"key":"2502_CR26","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1111\/cas.12501","volume":"105","author":"T Okusaka","year":"2014","unstructured":"Okusaka T, Ikeda M, Fukutomi A et al (2014) Phase II study of FOLFIRINOX for chemotherapy-na\u00efve Japanese patients with metastatic pancreatic cancer. Cancer Sci 105:1321\u20131326. https:\/\/doi.org\/10.1111\/cas.12501","journal-title":"Cancer Sci"},{"key":"2502_CR27","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s00280-018-3577-9","volume":"81","author":"M Ozaka","year":"2018","unstructured":"Ozaka M, Ishii H, Sato T et al (2018) A phase II study of modified FOLFIRINOX for chemotherapy-na\u00efve patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol 81:1017\u20131023. https:\/\/doi.org\/10.1007\/s00280-018-3577-9","journal-title":"Cancer Chemother Pharmacol"},{"key":"2502_CR28","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1093\/annonc\/mdz402","volume":"30","author":"C Morizane","year":"2019","unstructured":"Morizane C, Okusaka T, Mizusawa J et al (2019) Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced\/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. Ann Oncol 30:1950\u20131958. https:\/\/doi.org\/10.1093\/annonc\/mdz402","journal-title":"Ann Oncol"},{"key":"2502_CR29","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1002\/jhbp.1219","volume":"30","author":"T Ioka","year":"2022","unstructured":"Ioka T, Kanai M, Kobayashi S et al (2022) Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401-MITSUBA). J Hepatobiliary Pancreat Sci 30:102\u2013110. https:\/\/doi.org\/10.1002\/jhbp.1219","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2502_CR30","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.clcc.2018.01.011","volume":"17","author":"E Oki","year":"2018","unstructured":"Oki E, Kato T, Bando H et al (2018) A multicenter clinical phase II study of FOLFOXIRI plus bevacizumab as first-line therapy in patients with metastatic colorectal cancer: QUATTRO study. Clin Colorectal Cancer 17:147\u2013155. https:\/\/doi.org\/10.1016\/j.clcc.2018.01.011","journal-title":"Clin Colorectal Cancer"},{"key":"2502_CR31","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s10147-020-01811-w","volume":"26","author":"K Shinozaki","year":"2021","unstructured":"Shinozaki K, Yamada T, Nasu J et al (2021) A phase II study of FOLFOXIRI plus bevacizumab as initial chemotherapy for patients with untreated metastatic colorectal cancer: TRICC1414 (BeTRI). Int J Clin Oncol 26:399\u2013408. https:\/\/doi.org\/10.1007\/s10147-020-01811-w","journal-title":"Int J Clin Oncol"},{"key":"2502_CR32","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/S1470-2045(15)00122-9","volume":"16","author":"C Cremolini","year":"2015","unstructured":"Cremolini C, Loupakis F, Antoniotti C et al (2015) FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 16:1306\u20131315. https:\/\/doi.org\/10.1016\/S1470-2045(15)00122-9","journal-title":"Lancet Oncol"},{"key":"2502_CR33","doi-asserted-by":"publisher","first-page":"18811","DOI":"10.18632\/oncotarget.24702","volume":"9","author":"H Satake","year":"2018","unstructured":"Satake H, Sunakawa Y, Miyamoto Y et al (2018) A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11. Oncotarget 9:18811\u201318820. https:\/\/doi.org\/10.18632\/oncotarget.24702","journal-title":"Oncotarget"},{"key":"2502_CR34","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.3395","author":"C Morizane","year":"2022","unstructured":"Morizane C, Machida N, Honma Y et al (2022) Effectiveness of etoposide and cisplatin vs irinotecan and cisplatin therapy for patients with advanced neuroendocrine carcinoma of the digestive system. JAMA Oncol. https:\/\/doi.org\/10.1001\/jamaoncol.2022.3395","journal-title":"JAMA Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02502-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-024-02502-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02502-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T08:23:31Z","timestamp":1716798211000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-024-02502-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,5]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["2502"],"URL":"https:\/\/doi.org\/10.1007\/s10147-024-02502-6","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,5]]},"assertion":[{"value":"30 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Eishi Baba received honoraria from Chugai Pharmaceutical Co., Ltd. and Daiichi Sankyo Co., Ltd., and research funding from Taiho Pharmaceutical Co., Ltd. and Chugai Pharmaceutical Co., Ltd. Yukinori Ozaki received honoraria from Daiichi Sankyo Co., Ltd., Pfizer Japan Inc., Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., and Kyowa Kirin Co., Ltd. Eiki Ichihara received honoraria from Eli Lilly Japan K.K. and research funding from MSD K.K., Ono Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., and Takeda Pharmaceutical Co., Ltd. Yuji Miura received honoraria from Ono Pharmaceutical Co., Ltd., MSD K.K., Takeda Pharmaceutical Co., Ltd., Eisai Co., Ltd., and Bristol Myers Squibb Co., Ltd., and research funding from MSD K.K. and Ono Pharmaceutical Co., Ltd. Shingo Yano received research funding from Otsuka Pharmaceutical Co., Ltd. Dai Maruyama received honoraria from Ono Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., Nippon Shinyaku Co., Ltd., Eisai Co., Ltd., Mundipharma, Kyowa Kirin Co., Ltd., Chugai Pharmaceutical Co., Ltd., Zenyaku Holdings Co., Ltd., MSD K.K., SymBio Pharmaceutical Ltd., Sanofi K.K., AbbVie Inc., Takeda Pharmaceutical Co., Ltd., AstraZeneca K.K., Bristol Myers Squibb Co., Ltd., and Genmab K.K., and research funding from Amgen K.K., Astellas Pharma Inc., Biopharma Co., Ltd., Novartis Pharmaceutical K.K., Kyowa Kirin Co., Ltd., Ono Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Janssen Pharmaceutical K.K., Takeda Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Sanofi K.K., Bristol Myers Squibb Co., Ltd., AbbVie Inc., Eisai Co., Ltd., MSD K.K., Taiho Pharmaceutical Co., Ltd., AstraZeneca K.K., Eli Lilly Japan K.K., and Genmab K.K. Tetsuhiro Yoshinami received honoraria from Kyowa Kirin Co., Ltd., Pfizer Japan Inc., Chugai Pharmaceutical Co., Eli Lilly Japan K.K., MSD K.K., AstraZeneca K.K., and Eisai Co., Ltd. Takashi Motohashi received honoraria from AstraZeneca K. K., Chugai Pharmaceutical Co., and Myriad Genetics G. K. Toshio Kubo has received honoraria from Chugai Pharmaceutical Co.\u00a0Takahiro Kimura received honoraria from Sanofi K.K. Shinji Nakao received honoraria from Kyowa Kirin Co., Ltd. Atsushi Sato received honoraria from Chugai Pharmaceutical Co., and Taiho Pharmaceutical Co., Ltd., and received scholarship donations from Chugai Pharmaceutical Co., and Taiho Pharmaceutical Co., Ltd. Toshimi Takano received honoraria from Daiichi Sankyo Co., Ltd., Chugai Pharmaceutical Co., and Eli Lilly Japan K.K. Kenji Tsuchihashi received honoraria from Ono Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Taiho Pharmaceutical Co., Ltd., and Novartis Pharmaceutical K.K.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}